Adiponectin inhibits VEGF-A in prostate cancer cells

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4287-4292

  Gao, Qiruo ^a   Zheng, Junhua ^a   Yao, Xudong ^a   Peng, Bo ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adiponectin; AMPK; mTor; Prostate cancer; TSC2; Vascular endothelial growth factor A (VEGF A)

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; TUBERIN; VASCULOTROPIN A; ADIPONECTIN RECEPTOR; ADIPOR1 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ADIPONECTIN; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938971718     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3067-1     Document Type: Article

References (31)

1. Saylor PJ. Prostate cancer: the androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10:126–8.
2. Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer J. 2013;19:19–24.
3. Beltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2013;19:517–23.
4. Xin L. Cells of origin for cancer: an updated view from prostate cancer. Oncogene. 2013;32:3655–63.
5. Huang S, Liao Q, Li L, Xin D. PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.
6. Xia Q, Li C, Bian P, Wang J, Dong S. Targeting SMAD3 for inhibiting prostate cancer metastasis. Tumour Biol. 2014;35:8537–41.
7. Zhang Q, Hong B, Wu S, Niu T. Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour Biol. 2014.
8. Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012;16:365–76.
9. Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother. 2010;11:233–47.
10. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol. 2009;2:161–8.
11. Delongchamps NB, Peyromaure M. The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol. 2007;14:3669–77.
12. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology. 2006;68:244–8.
13. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–91.
14. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38:258–68.
15. Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors. 2009;35:332–7.
16. Xiao X, Prasadan K, Guo P, El-Gohary Y, Fischbach S, Wiersch J, et al. Pancreatic duct cells as a source of VEGF in mice. Diabetologia. 2014;57:991–1000.
17. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.
18. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63:800–9.
19. Perrier S, Jarde T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem. 2012;19:5501–12.
20. Buschemeyer 3rd WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331–43.
21. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46–53.
22. O'Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol. 2006;13 Suppl 2:11–7.
23. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006;28:737–45.
24. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–9.
25. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563–8.
26. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007;14:995–1005.
27. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90.
28. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–57.
29. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant. 2008;8:2212–8.
30. Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6:3011–4.
31. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19:1926–32.